Confirming reports published by Wall Street Journal earlier today, pharmaceutical giant Abbvie (NYSE: ABBV) said it would acquire Irish competitor Allergan (NYSE: AGN) for $63 billion.
As per the deal, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total consideration of $188.24 per Allergan Share.
The deal, which is expected to close early next year, represents approximately 45% premium over Allergan’s closing price on Monday.
Abbvie shares plunged 7.5% immediately following the announcement, while Allergan stock soared 28.5%.
AbbVie expects annual pre-tax synergies and other cost reductions from the deal of at least $2 billion in the third year while leaving investments in key growth franchises untouched.
Immediately following the deal, AbbVie shareholders are expected to have approximately 83% stake in AbbVie on a fully diluted basis, and the rest with Allergan shareholders.
Allergan CEO Brent Saunders said, “With 2019 annual combined revenue of approximately $48 billion, scale in more than 175 countries, an industry-leading R&D pipeline and robust cash flows, our combined company will have the opportunity to make even bigger contributions to global health than either can alone.”
The deal comes at a time the North Chicago, Illinois-based bio-pharmaceutical company is fast approaching the closure of its patent protection for its flagship product Humira. The immunology drug accounts for more than half of Abbvie’s total revenue.
READ: 10 biggest US mergers & acquisitions announced so far in 2019
With the acquisition, AbbVie could be looking to establish a strong base in the beauty drugs market.
This is the second massive deal to be announced in the bio-pharma segment this year. On January 3, Bristol-Myers Squibb (NYSE: BMY) said it would acquire its peer Celgene (NASDAQ: CELG) in a $74-billion cash-and-stock deal. However, this deal has been delayed, first due to shareholder opposition, and then due to antitrust concerns.
Most Popular
SBUX Earnings: All you need to know about Starbucks’ Q2 2024 earnings results
Starbucks Corporation (NASDAQ: SBUX) reported second quarter 2024 earnings results today. Consolidated net revenues declined 2% year-over-year to $8.6 billion. On a constant currency basis, revenue declined 1%. Global comparable store
AMD Earnings: A snapshot of Advanced Micro Devices’ Q1 2024 results
Semiconductor company Advanced Micro Devices, Inc. (NASDAQ: AMD) reported an increase in revenues and adjusted earnings for the first quarter of 2024. First-quarter earnings, on an adjusted basis, rose to
AMZN Earnings: Amazon Q1 profit jumps on higher sales; results beat
E-commerce giant Amazon.com Inc. (NASDAQ: AMZN) Tuesday reported a sharp increase in net sales and earnings for the first quarter of 2024. Net sales increased to $143.3 billion in the
Comments